Cited by 290Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment ApproachesInfective Endocarditis Diagnosis and Management

Propensity-Matched Comparisons of Clinical Outcomes After Transapical or Transfemoral Transcatheter Aortic Valve Replacement: A Placement of Aortic Transcatheter Valves (PARTNER)-I Trial Substudy

Open access
Blackstone, Eugene H., Suri, Rakesh M., Rajeswaran, Jeevanantham, Babaliaros, Vasilis, Douglas, Pamela S., Fearon, William F., Miller, D. Craig, Hahn, Rebecca T. +11 more·2015·Circulation

Abstract

Background—: The higher risk of adverse outcomes after transapical (TA) versus transfemoral (TF) transcatheter aortic valve replacement (TAVR) could be attributable to TA-TAVR being an open surgical procedure or to clinical differences between TA- and TF-TAVR patients. We compared outcomes after neutralizing patient differences using propensity score matching. Methods and Results—: From April 2007 to February 2012, 1100 Placement of Aortic Transcatheter Valves (PARTNER)-I patients underwent TA-TAVR and 1521 underwent TF-TAVR with Edwards SAPIEN balloon-expandable bioprostheses. Propensity matching based on 111 preprocedural variables, exclusive of femoral access morphology, identified 501 well-matched patient pairs (46% of possible matches), 95% of whom had peripheral arterial disease. Matched TA-TAVR patients experienced more adverse procedural events, longer length of stay (5 versus 8 days; P <0.0001), and slower recovery (New York Heart Association class I, 31% versus 38% at 30 days, equalizing by 6 months at 51% versus 47%); stroke risk was similar (3.4% versus 3.3% at 30 days and 6.0% versus 6.7% at 3 years); mortality was elevated for the first 6 postprocedural months (19% versus 12%; P =0.01); but aortic regurgitation was less (34% versus 52% mild and 8.9% versus 12% moderate to severe at discharge, P =0.001; 36% versus 50% mild and 10% versus 15% moderate to severe at 6 months, P <0.0001). Conclusions—: The likelihood of adverse periprocedural events and prolonged recovery is greater after TA-TAVR than TF-TAVR in vasculopathic patients after accounting for differences in cardiovascular risk factors, although stroke risk is equivalent and aortic regurgitation is less. As smaller delivery systems permit TF-TAVR in many of these patients, we recommend a TF-first access strategy for TAVR when anatomically feasible. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00530894.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.114.012525

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A transfemoral approach is associated with lower mortality and quicker recovery than alternative access approaches.

    “A transfemoral approach is associated with lower mortality and quicker recovery compared to alternative access approaches227–229.”

    From Calcific aortic stenosis (2016) · cites this paper as [229]

    The Conclusions report greater early mortality and prolonged recovery after transapical than transfemoral TAVR in matched high-risk or inoperable patients, nearly all with peripheral arterial disease. The claim broadens this finding to alternative access approaches generally; the same section says whether transaortic or subclavian access has lower risk remains to be studied. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Approximately two-thirds, or 56-75%, of TAVR procedures are performed using a transfemoral approach.

    “Approximately two-thirds (56–75%) of TAVR procedures are performed via a transfemoral approach226–229.”

    From Calcific aortic stenosis (2016) · cites this paper as [229]

    The Abstract (page unavailable) reports 1,521 transfemoral procedures among 2,621 PARTNER-I TAVR patients, or about 58%, which falls within the claimed range. It does not establish the full 56–75% range or show that this proportion applies to TAVR procedures generally. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Blackstone, E. H., Suri, R. M., Rajeswaran, J., Babaliaros, V., Douglas, P. S., Fearon, W. F., Miller, D. C., Hahn, R. T., Kapadia, S., Kirtane, A. J., Kodali, S. K., Mack, M., Szeto, W. Y., Thourani, V. H., Tuzcu, E. M., Williams, M. R., Akin, J. J., Leon, M. B., & Svensson, L. G.
Affiliations
Cleveland Clinic (US)
Venue
Circulation
Published
2015-06-02
Volume
131
Issue
22
Pages
1989-2000
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2698758261
Cited by
290
References
25
Citations by year
2026: 9 · 2025: 17 · 2024: 15 · 2023: 18 · 2022: 22 · 2021: 31 · 2020: 25 · 2019: 26 · 2018: 36 · 2017: 40 · 2016: 42 · 2015: 9
FWCI
30.74
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Valve Diseases and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Aortic Disease and Treatment Approaches
  • Health Sciences › Medicine › Epidemiology › Infective Endocarditis Diagnosis and Management
Keywords
aortic stenosis, PARTNER trial, aortic regurgitation, stroke risk, mortality, length of hospital stay, recovery, peripheral arterial disease, propensity score matching, procedural complications, Edwards SAPIEN
MeSH terms
Aged, Aged, 80 and over, Aortic Valve Stenosis, Female, Femoral Artery, Follow-Up Studies, Cardiac Catheterization, Humans, Longitudinal Studies, Male, Mortality, Treatment Outcome, Propensity Score, Transcatheter Aortic Valve Replacement

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review